To the Editor In their August 2014 editorial, “Warfarin, Genes, and the (Health Care) Environment,” Kazi and Hlatky1 point out a number of plausible reasons why pharmacogenetic data in this setting did not make a significant difference in the clinical outcomes measured. They then argue that effects on “surrogate markers, such as drug levels” are insufficient to recommend widespread pharmacogenetic testing, yet such testing, like any diagnostic testing, should not be performed in a “widespread” way but only when clinically indicated.
Pocinki AG. The Value of Pharmacogenetic Testing. JAMA Intern Med. 2015;175(2):314. doi:10.1001/jamainternmed.2014.7017
Best of JAMA Network 2022
Customize your JAMA Network experience by selecting one or more topics from the list below.